Macro Group Pharmaceuticals - Macro Capital S.A.E results, Q1 2025
Net profit, assets, equity and cash flow for Q1 2025, against the same period a year earlier, from the published financial statements.
Net profit22.38 millionEGP · +180.2% vs the same period a year earlier
Total assets712 millionEGP · +62.1% vs the same period a year earlier
Shareholders' equity100 millionEGP · +164.2% vs the same period a year earlier
Operating cash flow49.41 millionEGP · +310.2% vs the same period a year earlier
In short
- Macro Group Pharmaceuticals - Macro Capital S.A.E's net profit for Q1 2025 was about 22.38 million EGP, up +180.2% from -27.91 million EGP in Q1 2024.
- Total assets at the end of Q1 2025 were about 712 million EGP, and shareholders' equity about 100 million EGP.
- Operating cash flow for Q1 2025 was positive at 49.41 million EGP.
Key lines against the same period a year earlier
This periodQ1 2024Change
Net profit22.38 million-27.91 million+180.2%
Gross profit125 million40.17 million+212.0%
Total assets712 million439 million+62.1%
Total liabilities612 million394 million+55.1%
Shareholders' equity100 million38.04 million+164.2%
Total liabilities and equity712 million432 million+64.7%
Operating cash flow49.41 million-23.5 million+310.2%
Investing cash flow-8.6 million-253 thousand−3300.6%
Financing cash flow55.17 million45.12 million+22.3%
Net change in cash95.97 million21.36 million+349.3%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Macro Group Pharmaceuticals - Macro Capital S.A.E's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy